Madrigal (MDGL) news

Paulson adds GOOGL in 2Q: 13F

John Paulson, the founder and portfolio manager of Paulson & Co. Inc., has made several notable adjustments to his investment portfolio in the second quarter of 2024, as revealed in his latest 13F filing. Among the key changes, Paulson increased his stake in Madrigal Pharmaceuticals Inc…

Paulson reduces MDGL, AAMI in 2Q: 13F

Paulson & Co Inc. reduced its stake in Madrigal Pharmaceuticals (MDGL) and Brightsphere Investment Group (AAMI) during the second quarter of 2026, according to latest SEC 13F filing . The firm sold $117 million worth of MDGL shares, marking a 10% reduction in its position, while trimming its AAMI…

Madrigal Pharmaceuticals Inc: BofA Global Research cuts price objective to $543 from $553

BofA Global Research has revised its price target for Madrigal Pharmaceuticals Inc (NASDAQ: MDGL), lowering it to $543 from $553, while maintaining a Neutral rating on the stock. The adjustment follows a reassessment of the company’s long-term revenue projections for Rezdiffra, its flagship therapy…

Madrigal Pharmaceuticals Q2 product revenue USD 364.252 million

Madrigal Pharmaceuticals reported second-quarter 2025 product revenue of $364.252 million, reflecting strong demand for its flagship drug, Rezdiffra . This represents a significant increase compared to the same period in 2024, when product revenue was $14.638 million . The year-to-date revenue for…

Madrigal Pharmaceuticals Inc: Canaccord Genuity raises target price to $587 from $578